Use of sPLA2 activity for the diagnosis of a cardiovascular event

US8187818B2 · kind B2 · utility

Assignees

• ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR
• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR

Inventors

• Alain Tedgui · Paris, FR
• Ziad Mallat · Paris, FR
• Joëlle Benessiano · Paris, FR

Key dates

• Filing date: Jul 31, 2007
• Grant date: May 29, 2012
• Expiry date: Jul 29, 2028

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/32
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

A method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, includes:—determining the sPLA2 activity of the patient as a first risk marker—determining at least the value of a second risk marker chosen among CRP level, IgM IC of apo B 100 level or IgM MDA-LDL level—determining the ratio (odds ratio) between the value of the sPLA2 activity and the value of the second risk marker and comparing it to a predetermined odds ratio, the odds ratio compared to the predetermined odds ratio being indicative of an increased risk of mortality or of a cardiac and/or vascular event. A new micro method adaptation for automated fluorimetric measurement of serum secretory phospholipase A2 is also disclosed.